<?xml version="1.0" encoding="UTF-8"?>
<p>Immunotherapy and kinase inhibitors are known as backbones for second-line systemic chemotherapy [
 <xref rid="B17-biomedicines-08-00060" ref-type="bibr">17</xref>]. In the past, chemotherapy represented the treatment option for advanced melanoma. Although attempts to improve patient responses by combination therapy failed, it is still used for palliative treatment of progressed melanomas [
 <xref rid="B18-biomedicines-08-00060" ref-type="bibr">18</xref>]. Dacarbazine, an alkylating agent, was approved by the FDA in 1974 for standard chemotherapy treatment of metastatic melanoma [
 <xref rid="B19-biomedicines-08-00060" ref-type="bibr">19</xref>]. Despite moderate results, dacarbazine has been used as the sole standard of care, recently (in clinical trials) in combination with other chemotherapies and immunotherapies (ClinicalTrials.gov) [
 <xref rid="B20-biomedicines-08-00060" ref-type="bibr">20</xref>]. Temozolomide (TMZ), an active metabolite of dacarbazine, has been applied in advanced melanoma [
 <xref rid="B20-biomedicines-08-00060" ref-type="bibr">20</xref>].
</p>
